Anixa Biosciences Inc (ANIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 10/31
| 10-2024 | 07-2024 | 04-2024 | 01-2024 | 10-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,271 | 1,225 | 995 | 998 | 915 |
| Marketable Securities | 18,653 | 19,520 | 22,244 | 22,800 | 22,929 |
| Receivables | 173 | 410 | 218 | 391 | 270 |
| TOTAL | $21,362 | $22,670 | $24,214 | $25,219 | $25,356 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 229 | 238 | 141 | 153 | 166 |
| TOTAL | $229 | $238 | $141 | $153 | $166 |
| Total Assets | $21,591 | $22,908 | $24,355 | $25,372 | $25,522 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 525 | 302 | 215 | 364 | 206 |
| Accrued Expenses | 1,946 | 1,678 | 1,410 | 1,242 | 1,770 |
| TOTAL | $2,500 | $2,004 | $1,681 | $1,660 | $2,028 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 233 | 251 | 134 | 143 | 154 |
| TOTAL | $203 | $213 | $93 | $108 | $123 |
| Total Liabilities | $2,703 | $2,217 | $1,774 | $1,768 | $2,151 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 32,197 | 32,179 | 32,006 | 31,900 | 31,700 |
| Common Shares | 322 | 321 | 320 | 318 | 311 |
| Retained earnings | -240,750 | -237,867 | -234,590 | -231,451 | -228,196 |
| Other shareholders' equity | -1,116 | -1,080 | -1,042 | -1,001 | -966 |
| TOTAL | $18,888 | $20,691 | $22,581 | $23,604 | $23,371 |
| Total Liabilities And Equity | $21,591 | $22,908 | $24,355 | $25,372 | $25,522 |